This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kendall Law Group Investigates Genoptix, Inc. Acquisition For Shareholders

Kendall Law Group, led by former federal judge Joe Kendall, is investigating Genoptix, Inc. (Nasdaq: GXDX) for shareholders in connection with the proposed acquisition by Novartis. The national securities firm’s investigation seeks to determine whether Genoptix and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a Genoptix shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at

On January 24, 2011, Genoptix announced the definitive merger agreement under which the company would be acquired by Novartis, in a transaction valued at approximately $470 million. Under the terms of the agreement, Genoptix stockholders will receive $25.00 in cash for each share of Genoptix/GXDX common stock held. The offer represents a 27% premium over Genoptix’s Friday closing price of $19.76. According to Thompson/First Call, analysts have set a price target as high as $28.00 per share for Genoptix stock. The firm seeks to determine whether the transaction provides proper value for the company.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,832.28 +42.09 0.25%
S&P 500 1,977.99 -1.93 -0.10%
NASDAQ 4,736.01 -12.3510 -0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs